HA22-LR has potent antitumor activity. SCID mice with CA46 xenograft tumors were treated every other day 3 times (on days 6, 8, and 10) intravenously with PBS (×; solid line), 0.3 mg/kg HA22 (○; solid line), or HA22-LR at 1.0 (▲; dashed line), 1.75 (□; solid line), or 2.5 (*; dashed line) mg/kg. Arrows indicate days when treatment was administered. Tumor size was measured over the course of 40 days. Points represent the mean tumor size of all mice in the treatment group. Error bars show the 95% confidence interval of each mean value.